Trial Profile
Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate GSK 2115160A in Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 2321138A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 30 Oct 2008 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.
- 30 Oct 2008 Actual patient number (420) added as reported by ClinicalTrials.gov.
- 30 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.